Day two of the 1st Annual Life Sciences Forum in London saw panellists discuss the European Unitary Patent and the Unified Patent Court.
Law firm Maurice Blackburn revealed on Monday that it will appeal against an Australian court decision that backed Myriad Genetics’ ownership of a human gene mutation linked to breast cancer.
India’s patent authorities have dealt a blow to German pharma company Bayer by refusing to overturn an order forcing the company to license one of its patented drugs.
ViiV Healthcare, a public health joint venture between GlaxoSmithKline, Shionogi and Pfizer, has signed up to the Medicines Patent Pool (MPP) to provide greater access to affordable AIDS treatments in developing countries.
The UK government announced a change to the Patent Act on Tuesday that will allow parties to run drug trials without infringing other parties’ patents.
The US Food and Drug Administration has approved two generic versions of Reckitt Benckiser’s heroin replacement tablet Suboxone – despite Reckitt’s claims that the product is unsafe.
In a report published by Thomson Reuters on February 20, the BRICK nations were shown to be filing almost as many patents as the G7 nations in 2011.
England’s Court of Appeal has affirmed a 2012 High Court ruling that pharmaceutical company Genentech’s patent covering human vascular endothelial growth factor antagonists is valid and has been infringed by Regeneron and Bayer Pharmaceutical’s drug Eylea.
The US Court of Appeals for the Federal Circuit has affirmed a 2012 ruling that AstraZeneca’s patent for antipsychotic drug Seroquel XR is valid and has been infringed by companies selling competing generics.
Israeli company Teva Pharmaceuticals could be forced to pay more than $2 billion in damages for selling a generic version of Nycomed and Pfizer’s heartburn reliever Protonix before the drug’s patent exclusivity expired in the US.